B of A Securities Maintains Insmed (INSM) Buy Recommendation
Nasdaq Fintel reports that on September 6, 2023, B of A Securities maintained coverage of Insmed (NASDAQ:INSM) with a Buy recommendation.
Analyst Price Forecast Suggests 57.34% Upside
As of August 31, 2023, the average one-year price target for Insmed is 41.58. The forecasts range from a low of 30.30 to a high of $54.60. The average price target represents an increase of 57.34% from its latest reported closing price of 26.43.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Insmed is 338MM, an increase of 25.53%. The projected annual non-GAAP EPS is -4.04.
- For more in-depth coverage of Insmed, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 516 funds or institutions reporting positions in Insmed. This is a decrease of 24 owner(s) or 4.44% in the last quarter. Average portfolio weight of all funds dedicated to INSM is 0.21%, an increase of 19.04%. Total shares owned by institutions increased in the last three months by 0.18% to 167,260K shares. The put/call ratio of INSM is 3.81, indicating a bearish outlook.
